Neuroinflammation

Coya Therapeutics SAB Chairman Dr. Stanley Appel, M.D. Selected as Speaker at the Society of Neuroimmune Pharmacology Conference

Retrieved on: 
Monday, January 29, 2024
Health, Other Science, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, FTD, Macrophage, Therapy, Survival, Neuroinflammation, COYA, PD, Amyotrophy, Conference, Neurodegenerative disease, Prevalence, Frontotemporal dementia, Pharmacology, Immune system, Pharmaceutical industry

Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Dr. Stanley Appel, M.D., Chairman of Coya’s Scientific Advisory Board, has been invited to participate at the upcoming Society of Neuroimmune Pharmacology Conference to be held on March 10-13, 2024 in Charleston, SC.

Key Points: 
  • Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Dr. Stanley Appel, M.D., Chairman of Coya’s Scientific Advisory Board, has been invited to participate at the upcoming Society of Neuroimmune Pharmacology Conference to be held on March 10-13, 2024 in Charleston, SC.
  • Dr. Appel’s presentation will be on Monday, March 11, 2024 and is titled Immunomodulatory Therapy in Neurodegenerative Disease: Lessons from ALS.
  • He will discuss the critical role of proinflammatory macrophages, reduced regulatory T-lymphocyte (Treg) numbers and suppressive function, and the potential of COYA 302 therapy.
  • COYA 302 combines subcutaneous CTLA-4 Ig to inhibit pro-inflammatory macrophages with subcutaneous Low Dose IL-2 to enhance endogenous Tregs.

Myrobalan Therapeutics Completes Series A Financing of $24 Million to Develop Potentially First-in-Class CNS Therapeutics with Restorative Potential

Retrieved on: 
Wednesday, January 10, 2024
Health, Neurology, Research, Pharmaceutical, Science, Biotechnology, Constellation, Patient, Therapy, Biology, Remyelination, Drug design, ALS, Broad Institute, Multiple sclerosis, Partnership, Harvard Medical School, National academy, GPR17, Venture, Neuroinflammation, MIT, Sympathetic nervous system, Drug development, TYK2, Traffic barrier, Harvard University, Capital, Limited partnership, CNS, Pharmaceutical industry

Myrobalan has the potential to overcome such obstacles with the development of highly selective, brain-penetrant, orally available compounds against promising novel targets involved in demyelination and neuroinflammation.

Key Points: 
  • Myrobalan has the potential to overcome such obstacles with the development of highly selective, brain-penetrant, orally available compounds against promising novel targets involved in demyelination and neuroinflammation.
  • These currently untreatable disease mechanisms have been linked to multiple sclerosis (MS), Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), and several rare neurological conditions.
  • “Our deep understanding of remyelination and neuroinflammation has broad application in high-unmet need CNS diseases,” said Dr. Jing Wang, CEO & Co-Founder, Myrobalan Therapeutics.
  • Myrobalan Therapeutics' unique strategy holds great promise in overcoming challenges associated with central nervous system diseases.

Denali Therapeutics Announces Key Anticipated 2024 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases

Retrieved on: 
Monday, January 8, 2024
CSF, Lysosomal storage disease, Cerebrospinal fluid, Risk, Sanfilippo syndrome, Amyloid, BBB, UC, Sanfilippo, Manuscript, ETV, ALS, OTV, SNCA, IDS, Asos, Conference, Cognition, RIPK1, Fluid mechanics, Neuroinflammation, Premedication, Glycogen storage disease, Amyloid beta, SGSH, Therapy, COMPASS, Traffic barrier, Hunting, N-sulfoglucosamine sulfohydrolase, Hunter syndrome, ISR, NewCo, Amyloid-related imaging abnormalities, Inflammation, CNS, Neurodegenerative disease, Takeda, Biomarker, Alpha-synuclein, K2, Biology, DSM-IV codes, LUMA, Brain, MPS, Investigational New Drug, PTV, ARIA, Nerve, AFL, Pathology, MPS II, Interim, BioRxiv, Plaque, MAPT, LRRK2, Elevator mechanic

The global Phase 2/3 COMPASS study continues to recruit up to 54 participants with neuronopathic and non-neuronopathic MPS II.

Key Points: 
  • The global Phase 2/3 COMPASS study continues to recruit up to 54 participants with neuronopathic and non-neuronopathic MPS II.
  • Upon completion of the ongoing Phase 1/2 study, and together with data from COMPASS, this combined data package is intended to support registration.
  • Increased RIPK1 activity in the CNS is hypothesized to drive neuroinflammation and cell necroptosis and to contribute to neurodegeneration.
  • Denali will maintain ownership of and continue to advance its current portfolio of clinical stage small molecule programs.

NKGen Biotech, Inc. Announces Dosing of First Patient in its Phase 1/2a Trial with Autologous NK Cell Product, SNK01, for the Treatment of Moderate Alzheimer’s Disease

Retrieved on: 
Thursday, December 28, 2023
Neuroinflammation, Patient, Safety, Therapy, NK, Pharmaceutical industry

SANTA ANA, Calif., Dec. 28, 2023 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic, and CAR-NK natural killer cell therapeutics, today announced the dosing of the first patient in its Phase 1/2a trial evaluating SNK01, a cryopreserved autologous, non-genetically modified NK cell therapy product with enhanced cytotoxicity and activating receptor expression. This Phase 1/2a trial is evaluating safety and tolerability in participants with moderate AD.

Key Points: 
  • SNK01 consists of a non-genetically modified NK cell product with enhanced cytotoxicity and activating receptor expression for the treatment of moderate AD.
  • Initial patient in this Phase 1/2a trial received 6 billion cells, 50% more than the maximum dosing from the Phase 1 trial.
  • The Phase 1 is an open label safety evaluation to determine the maximum tolerated dose and/or recommended Phase 2 dose of SNK01.
  • The Phase 2 is a randomized double-blind trial evaluating the safety and efficacy of SNK01 in moderate AD.

INmune Bio Provides Update Regarding Global Alzheimer’s Phase II Clinical Trial and Clinical Hold Issued by the United States FDA

Retrieved on: 
Monday, December 18, 2023
Phase, TNF, FDA, Inflammation, Neuroinflammation, Biomarker, Patient, Pharmaceutical industry

Boca Raton, Florida, Dec. 18, 2023 (GLOBE NEWSWIRE) --  INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company targeting microglial activation and neuroinflammation as a cause of Alzheimer’s disease (AD) with XProTM (XPro1595; pegipanermin), a dominant-negative inhibitor of soluble TNF, is on track to complete enrollment of its Phase II clinical trial in patients with early Alzheimer’s Disease and biomarkers of inflammation in 2024. The Company received notification by the FDA that the US Phase II trial remains on full clinical hold pending a request for additional information on long-term potency.  

Key Points: 
  • In the US, the previously identified clinical hold issues have been successfully addressed however the Phase II study remains on clinical hold pending additional information on long-term stability which the Company will provide before the end of 2023.
  • The Company received notification by the FDA that the US Phase II trial remains on full clinical hold pending a request for additional information on long-term potency.
  • “We remain discussion with the FDA regarding the clinical hold,” said RJ Tesi, CEO of INmune Bio.
  • To date, the FDA remains the only regulatory agency to put the Phase II clinical trial on hold.

New Insights Revealed On Tissue-Dependent Roles of JAK Signaling in Inflammation

Retrieved on: 
Thursday, December 21, 2023
Biology, MTR, Dermatitis, DOI, Hospital, Atopic dermatitis, Protein, FAAD, Family, Immune system, Division, Neuron, Sensation, Allergy, British Columbia Children's Hospital, Research, Cell, DRS, University of British Columbia, Sol, Disease, Tissue, Mouse, Rheumatoid arthritis, Cancer, Inflammation, Asthma, FRCPC, University, JAK, Mutation, Faculty, Hypereosinophilic syndrome, Nervous system, Gene, Lung, MBBS, Neuroinflammation, Patient, JAK1, Medical school, Diagnosis, Canada Research Chair, STAT6, Signal, Pharmaceutical industry

NEW YORK, Dec. 21, 2023 /PRNewswire-PRWeb/ -- Researchers at the Icahn School of Medicine at Mount Sinai have gained a deeper understanding of the nuanced roles of JAK inhibitors, or modulators, in inflammation across various cell types and tissues. Their findings suggest a more precise approach is required to potentially expand JAK inhibitor use to a wider range of allergy and inflammatory disorders. Details on the findings were published in the December 21, 2023, issue of the journal Cell (DOI: 10.1016/j.cell.2023.11.027).

Key Points: 
  • Their findings suggest a more precise approach is required to potentially expand JAK inhibitor use to a wider range of allergy and inflammatory disorders.
  • Current JAK inhibitors work well against inflammation in diseases like eczema, but the study suggests a need for a nuanced approach in modulating JAK activity for conditions like asthma.
  • The study showed that activated JAK1 signaling has tissue-specific effects, including an unexpected immunoregulatory role in lung sensory neurons, where it suppresses lung inflammation.
  • In the lung neurons of the mice, the JAK1 mutant protein reduced inflammation caused by exposure to mold by producing substances that suppress inflammation.

Athira Pharma Presents Preclinical Data Highlighting Fosgonimeton’s Neuroprotective Effects Against Amyloid-β-Induced Pathological Alterations and Neuroinflammation in Models of Alzheimer’s Disease

Retrieved on: 
Wednesday, November 15, 2023
Molecule, ISCB Senior Scientist Award, Annual general meeting, HGF, Cell proliferation, Athira Pharma, Neuron, Microglia, LPS, Oxidative stress, Neurogenesis, Neuroinflammation, Society, Pharmaceutical industry, Medical imaging, Neuroscience, Neurotrophic factors

“We continue to build the body of preclinical evidence supporting the continued development of fosgonimeton to treat AD and other debilitating neurodegenerative diseases,” said Kevin Church, Ph.D., Chief Scientific Officer, Athira Pharma.

Key Points: 
  • “We continue to build the body of preclinical evidence supporting the continued development of fosgonimeton to treat AD and other debilitating neurodegenerative diseases,” said Kevin Church, Ph.D., Chief Scientific Officer, Athira Pharma.
  • “Our latest data demonstrate consistent neuroprotective effects of fosgonimeton and provide insights into the mechanisms by which it preserves neurons from degeneration and reduces neuroinflammation.
  • Wei Wu, Ph.D., Senior Scientist II, Athira Pharma, presented preclinical research demonstrating the cellular mechanisms by which fosgonimeton induces anti-inflammatory effects in BV2 microglia cells.
  • The anti-inflammatory effects of fosgonimeton demonstrated in these models suggest it may have the potential to help reduce neuroinflammation, a key pathological feature of several neurodegenerative diseases.

Athira Pharma Reports Third Quarter 2023 Financial Results and Pipeline and Business Updates

Retrieved on: 
Thursday, November 9, 2023
ACT, Walter, Investment, Neuromuscular junction, Patient, Pathology, Conference, Cognition, R, ADAS, Inflammation, AFL, Society, Glial fibrillary acidic protein, Food, Toxicity, HGF, IND, Administration, GFAP, Excitotoxicity, Alzheimer's disease, G&A, Microglia, Communication, Neuroinflammation, Athira Pharma, Research and development, Brain cell, Biomarker, Riluzole, ALS, Frontotemporal dementia, Washington Convention Center, Drug development, AAIC, Enzyme inhibitor, Plasma, Mouse, Doctor of Philosophy, FDA, Neurodegenerative disease, Survival, Central nervous system, GST, Fine chemical, Pharmaceutical industry, Medical imaging, Cryptocurrency, Neuroscience, Athira

BOTHELL, Wash., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today reported financial results for the quarter ended September 30, 2023, and provided pipeline and business updates.

Key Points: 
  • BOTHELL, Wash., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today reported financial results for the quarter ended September 30, 2023, and provided pipeline and business updates.
  • R&D expenses were $27.2 million for the quarter ended September 30, 2023, compared with $17.0 million for the quarter ended September 30, 2022.
  • G&A expenses were $7.8 million for the quarter ended September 30, 2023, compared with $7.2 million for the quarter ended September 30, 2022.
  • The increase was primarily due to increases in personnel expenses, partially offset by a decrease in business development expenses.

NanoString Technologies to Present Portfolio of Cutting-edge Brain Research and Novel Spatial Biology Applications for Neuroscience

Retrieved on: 
Thursday, November 9, 2023
Technology, Biotechnology, Health, Neurology, Stem Cells, Research, Software, Infectious Diseases, General Health, Internet, Genetics, Health Technology, Science, Data Management, NanoString Technologies, Society, Neuro, Abcam, SMI, University, Neuroinflammation, Max Planck, Poster, HIV disease progression rates, RNA, Medical imaging, Vaccine

NanoString Technologies, a leading provider of life sciences tools for discovery and translational research, announced today it will present at the Society for Neuroscience (SfN) annual meeting a large body of new brain research powered by its industry-leading digital spatial profiling and spatial imaging platforms.

Key Points: 
  • NanoString Technologies, a leading provider of life sciences tools for discovery and translational research, announced today it will present at the Society for Neuroscience (SfN) annual meeting a large body of new brain research powered by its industry-leading digital spatial profiling and spatial imaging platforms.
  • The presentation will be delivered by Caleb Stokes, M.D., Ph.D. of the University of Washington at NanoSymposium (NANO22.08) on Sunday, Nov. 12, from 2:45-3:00 PM EST.
  • “With this unprecedented capability, researchers will gain critical insights into single cell signaling for healthy and diseased brain tissue.
  • The opportunity for future patient benefit is enormous,” said Brad Gray, President and CEO of NanoString.

BrainStorm Cell Therapeutics to Present at 6th Annual ALS Research Symposia

Retrieved on: 
Friday, November 17, 2023
Biomarker, Safety, Brainstorm, CSF, Cedars-Sinai Medical Center, Research, California Pacific Medical Center, Event, University, MD, Survival, Neuroinflammation, Mayo Clinic, University of California, Neuroprotection, Cerebrospinal fluid, HIV disease progression rates, Hospital, Medical imaging, ALS

NEW YORK, Nov. 17, 2023 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced a podium presentation and panel discussion at the 6th Annual ALS Research Symposium hosted by ALS ONE. The presentation will feature new analyses from the NurOwn placebo-controlled Phase 3 amyotrophic lateral sclerosis (ALS) trial that highlight the biological effect of NurOwn through CSF biomarker data. The presentation, titled, "NurOwn for ALS: Biomarker exploration of NurOwn multimodal mechanism of action on neuroinflammation, neuroprotection and neurodegeneration" will be presented by Bob Dagher, MD, Executive Vice President and Chief Development Officer at BrainStorm.

Key Points: 
  • Presentation on NurOwn Phase 3 data demonstrating evidence of biological effect in ALS; Biomarker data reinforce clinical outcomes
    NEW YORK, Nov. 17, 2023 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced a podium presentation and panel discussion at the 6th Annual ALS Research Symposium hosted by ALS ONE.
  • The presentation will feature new analyses from the NurOwn placebo-controlled Phase 3 amyotrophic lateral sclerosis (ALS) trial that highlight the biological effect of NurOwn through CSF biomarker data.
  • The presentation, titled, "NurOwn for ALS: Biomarker exploration of NurOwn multimodal mechanism of action on neuroinflammation, neuroprotection and neurodegeneration" will be presented by Bob Dagher, MD, Executive Vice President and Chief Development Officer at BrainStorm.
  • A copy of the presentation will be available on the Events & Presentation page of Brainstorm's corporate website following the presentation.